The growing threat of bacterial resistance has significantly reduced the efficacy of conventional antibiotics, necessitating the development of novel antibacterial agents with distinct mechanisms of action. In this study, we report the design, synthesis, and biological evaluation of a new class of quinoline-thiazolidinone conjugates as potent antibacterial agents. Employing a molecular hybridization strategy, a series of conjugates was synthesized by incorporating various aryl and heterocyclic derivatives into quinoline and thiazolidinone scaffolds with 62-80 % yield. The antibacterial activity of these compounds was assessed against eight Gram-positive and Gram-negative bacterial strains. Notably, compounds 12 and 27 demonstrated potent activity, particularly against Escherichia coli, exhibiting low minimum inhibitory concentrations (MICs), i.e. 1.56 μg/mL. Mechanistic studies revealed their ability to inhibit biofilm formation by over 85 % inhibition, disrupt bacterial membranes, induce oxidative stress, and cause metabolic and DNA damage. Cytotoxicity assays confirmed their safety in normal mammalian cells, ranging from 3.72 to 6.80 % and 2.32-4.96 % for derivatives 12 and 27, respectively, while time-kill kinetics indicated rapid bactericidal effects within 120 min for conjugate 12 and 90 min for conjugate 27. Furthermore, spectroscopic and computational analyses confirmed strong binding interactions with DNA (Kb = 1.02 × 105 M-1 for 12 and 3.3 × 105 M-1 for 27) and human serum albumin (Kb = 2.49 × 105 M-1 and 4.14 × 105 M-1), supporting their potential for effective bioavailability and systemic transport. Overall, these findings position quinoline-thiazolidinone conjugates, especially compounds 12 and 27, as promising lead candidates for addressing antibiotic resistance in bacterial infections.